The PubMed, Web of Science, and Scopus databases were utilized for any studies related to Rmab therapy in CNS vasculitis from January 2015 to May 2024, using the following combination of Medical Subject Headings (MeSH) phrases: ("Primary CNS Vasculitis," OR "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis," OR "ANCA-associated Vasculitis," OR "Microscopic Polyangiitis," OR "Polyangiitis" OR "Wegener's Granulomatosis" OR "Granulomatosis with Polyangiitis" OR "PR3-AAV" OR "MPO-AAV") AND ("Anti-CD20," OR "Rituximab"). This evidence concerns the gene MPO and microscopic polyangiitis.